Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer

Shu-Wei HuMing-Hsin YehYu-Hao HeYa-Ling WeiFang-Ju ChengYi-Lun YehThanh Kieu HuynhPei-Tong LiuDai-Wei HuTzu-Hsuan ChangBo-Wei WangBo-Rong ChenMei-Chun LinDer-Yen LeeYi-Hsien HsiehYuan-Man HsuChih-Hsin TangPing-Chih HoMien-Chie HungWei-Chien Huang2026-03-102026-03-102025-1110.1016/j.xcrm.2025.102429https://scholars.csmu.edu.tw/handle/123456789/5394Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancerjournal-article